通络壮骨散治疗乳腺癌内分泌治疗后骨质疏松的研究  

A study on treating osteoporosis after endocrine therapy for breast cancer with Tongluo Zhuanggu San

作　　者：张广路[1] 方玲子[1] 卓超林 陈启庭[1] 蔡俊媛 宋亚中 金宇[1] Zhang Guanglu

机构地区：[1]深圳市第二人民医院,广东深圳518000

出　　处：《中医临床研究》2020年第22期71-73,共3页Clinical Journal Of Chinese Medicine

基　　金：广东省中医药局科研项目资助(编号20192079)。

摘　　要：目的:观察中药通络壮骨散外敷治疗乳腺癌内分泌治疗后骨质疏松的疗效。方法:220例乳腺癌内分泌治疗后骨质疏松患者,随机分为治疗组和对照组,每组110例,对照组口服碳酸钙D3片,治疗组在对照组基础上外敷通络壮骨散。疗程均为25周,对比治疗前后腰椎骨密度的变化。结果:两组骨密度均增加(P<0.05),治疗组骨密度高于对照组(P<0.05);并两组的I型原骨胶原蛋白N-端肽(s-PINP)均降低(P<0.05),治疗组s-PINP低于对照组(P<0.05);两组碱性磷酸酶(ALP)降低、骨钙素(BGP)增加(P<0.05),治疗组ALP低于对照组,BGP高于对照组(P<0.05)。结论:钙剂联合中药通络壮骨散外敷治疗乳腺癌内分泌治疗后骨质疏松效果更好。Objective:To observe the effects of Tongluo Zhuanggu San(通络壮骨散)on osteoporosis after endocrine therapy for breast cancer.Methods:220 patients were randomly divided into the treatment group and control group,110 patients in each.The control group was given calcium carbonate D3 tablets orally.The treatment group was given external application with Tongluo Zhuanggu San more.Results:The bone mineral density was increased in both groups(P<0.05),and that in the treatment group was higher than the control group(P<0.05).Moreover,s-PINP in both groups was decreased(P<0.05),and s-PINP in the treatment group was lower than the control group(P<0.05).ALP was decreased,and BGP was increased in groups(P<0.05),ALP in the treatment group was lower than the control group,and BGP was higher than the control group(P<0.05).Conclusion:Tongluo Zhuanggu San plus Calcium on osteoporosis after endocrine therapy for breast cancer shows better effects.

关 键 词：乳腺癌 骨质疏松 内分泌治疗 中药外敷 

分 类 号：R322.72[医药卫生—人体解剖和组织胚胎学]